Denosumab Protects Bone Density in Breast Cancer Patients
One side effect experienced by breast cancer patients undergoing adjuvant aromatase inhibitor therapy is accelerated bone-loss and increased fracture risk. SCCA's Georgiana K. Ellis presented data at the San Antonio Breast Cancer Symposium that found that twice-yearly administration of denosumab led to significant increases bone mineral density. Read more